

The Examiner's attention is also respectfully directed to the rules of practice which Applicants understand to apply only to peptide sequences of four or more amino acid residues. For this reason, the shorter peptide linker or bridge also found in the specification, that has only three amino acid residues, has not been made a part of the enclosed Sequence Listing.

DECLARATIONS

As required under 37 C.F.R. §§1.821 through 1.825, Applicants' undersigned attorneys hereby state that the information recorded in the enclosed computer readable form is identical to the enclosed paper copy of the Sequence Listing.

As required under 37 C.F.R. §1.825, Applicants' undersigned attorneys hereby state that the enclosed replacement Sequence Listing does not include any new matter, and is believed to be fully supported by the application as filed.

CONCLUSION

No fee is believed to be owed for entry of this Response. Nevertheless, if it is determined that any fee is required, any such fee, and/or any deficiency or overpayment in any fee, should be charged or credited to Deposit Account No. 50-0217.

Respectfully submitted,

ROBERTS & MERCANTI, L.L.P.

By: 

Laurence Manber

Reg. No. 35,597

July 1, 2002

ROBERTS & MERCANTI, L.L.P.
EDC II
105 Lock Street, Suite 203
Newark, New Jersey 07103
973-627-0660 (Phone)
973-621-0774 (Facsimile)



COPY OF PAPERS
ORIGINALLY FILED

213.1079CIP3

APPENDIX I

The above provided revised claims are illustrated below, wherein brackets indicate deletions and underline indicates insertions.

7. (Revised) The compound of claim 6 wherein the peptide is Gly-Phe-Leu-Gly
(SEQ ID NO:1) or Gly-Phe-Leu.